Trial Profile
Graft-versus-host Disease Prophylaxis With Post-transplantation Cyclophosphamide and Ruxolitinib in Patients With Myelofibrosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Ruxolitinib (Primary) ; Busulfan; Fludarabine
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 03 Apr 2019 Status changed from active, no longer recruiting to completed.
- 26 Apr 2018 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.
- 26 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.